GC Biopharma recently announced its participation in the Seoul Pandemic X Summit 2026, where it presented its mRNA vaccine development strategy for future pandemic responses.
The event was organized to explore joint international responses to future pandemics. Various stakeholders participated in discussions on global cooperation frameworks and strategies for rapid vaccine development and supply.
At the summit, GC Biopharma shared updates on its proprietary mRNA-LNP platform and the progress of its COVID-19 vaccine development.
Since 2019, GC Biopharma has been conducting research on its mRNA-LNP platform using AI deep learning technology. The company has developed mRNA sequence design capabilities that maximize protein expression efficiency through its Codon Optimization Software, and enhanced mRNA drug delivery efficiency using artificial intelligence (AI)-based Lipid Nanoparticle (LNP) lipid structure and composition optimization techniques.
The COVID-19 mRNA vaccine candidate developed using this platform has demonstrated immune responses comparable to global vaccines in preclinical studies while maintaining stability.
Furthermore, GC Biopharma has completed the establishment of an end-to-end process, encompassing cell line development, mRNA synthesis, LNP formulation, final product manufacturing, and quality analysis.
Jae-wook Jeong, head of research and development (R&D) at GC Biopharma, stated that they’re building the foundation to respond swiftly to future pandemics based on the accumulated mRNA research capabilities and production infrastructure. It will continue the efforts to secure globally competitive vaccine development capabilities.
In late January, GC Biopharma completed the first participant dosing in a Phase 1 clinical trial for its COVID-19 mRNA vaccine. The company plans to submit an Investigational New Drug (IND) application for Phase 2 clinical trials in the second half of this year.
Additionally, GC Biopharma, in collaboration with the Korean Hemophilia Foundation, Seoul National University College of Pharmacy, and Samsung Medical Center, has been selected for the Advanced Bio Convergence Talent Development Project led by the Ministry of Health and Welfare. The consortium has begun developing the world’s first AI-based Clinical Decision Support System (CDSS) for predicting hemophilic arthropathy.